Trial Profile
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Eluxadoline (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors AbbVie; Allergan
- 19 Dec 2023 Planned number of patients changed from 120 to 95.
- 19 Dec 2023 Planned End Date changed from 15 Dec 2023 to 15 Dec 2026.
- 19 Dec 2023 Planned primary completion date changed from 15 Dec 2023 to 15 Dec 2026.